Adherence to somatostatin analog therapy for acromegaly
نویسندگان
چکیده
منابع مشابه
Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly.
Somatostatin analogs (SSA) with their potent antisecretory and antiproliferative effects are the main medical treatment option for patients with neuroendocrine tumors, such as gastroenteropancreatic and acromegaly-associated growth hormone secreting pituitary tumors. Although a good portion of acromegalic patients gets normalized after SSA treatment, strict hormonal control is not achieved in a...
متن کاملLow beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly.
OBJECTIVE The high expression of somatostatin receptor subtype 2 (SSTR2 also known as sst2) usually present in growth hormone (GH)-secreting adenomas is the rationale for therapy with somatostatin analogs (SSAs) in acromegaly. Although SSTR2 expression is a good predictor for biochemical response to SSA treatment, we still face tumors resistant to SSAs despite high SSTR2 expression. Recently, b...
متن کاملSuccessful pregnancy in a woman with acromegaly treated with somatostatin analog (octreotide) prior to surgical resection.
A 27-year-old woman with a GH-secreting pituitary macroadenoma was treated with continuous s.c. infusion of octreotide prior to surgical resection. Subsequently, she was found to be 6 months pregnant. Fetal echographs were normal, the newborn had no malformation, and postnatal development was normal.
متن کاملNovel Somatostatin Receptor Ligands Therapies for Acromegaly
Surgery is considered the treatment of choice in acromegaly, but patients with persistent disease after surgery or in whom surgery cannot be considered require medical therapy. Somatostatin receptor ligands (SRLs) octreotide (OCT), lanreotide, and the more recently approved pasireotide, characterized by a broader receptor ligand binding profile, are considered the mainstay in the medical manage...
متن کاملEffects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy.
OBJECTIVE In this study, the effect of high-dose octreotide LAR on glucose metabolism in patients with acromegaly was investigated. DESIGN A post-hoc analysis of a clinical trial enrolling 26 patients with acromegaly not controlled by standard maximal somatostatin analog (SSAs) dose and randomized to receive high-dose (60 mg/28 days) or high-frequency (30 mg/21 days) octreotide i.m. injecti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Meditsinskiy sovet = Medical Council
سال: 2021
ISSN: 2658-5790,2079-701X
DOI: 10.21518/2079-701x-2021-7-142-149